ClinicalTrials.gg
RecruitingNCT07280416INDICAUpdated Oct 26, 2026

Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer

An observational study in Cancer, Insomnia and Pain, sponsored by Centre Hospitalier Emile Roux. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Centre Hospitalier Emile Roux · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
260
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The diagnosis of cancer can be a major trigger for new sleep problems, especially insomnia, in people who did not have sleep issues before. Insomnia may appear early in the care pathway and can continue over time, often interacting with other physical or emotional symptoms.

The main goal of this preliminary study is to describe how insomnia develops during the first months after a cancer diagnosis in patients who had no sleep problems at the time of diagnosis. This will be done through regular follow-up over time.

A secondary aim is to identify the factors that may contribute to the onset or persistence of insomnia, such as the cancer treatments patients receive, as well as any medical or non-medical therapies used to manage sleep difficulties.

The study will also look at whether patients who develop sleep problems are referred to psychologists trained in specific therapies for insomnia, and how well they follow and adhere to these treatments.

02

Conditions studied

  • Cancer
  • Insomnia
  • Pain
  • Depression Anxiety Disorder
  • Quality of Life

Keywords

  • cancer
  • insomnia
  • pain
  • Depresion Anxiety disorder
  • longitudinal
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 260 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Centre Hospitalier Emile Roux is the lead sponsor of 20 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study includes adult patients (≥18 years) with a confirmed diagnosis of metastatic or non-metastatic cancer, who are scheduled to receive intravenous chemotherapy and/or immunotherapy (intravenous or subcutaneous). Eligible participants must be able to read and understand French, be covered by a social security system, and provide signed informed consent. Patients must not have pre-existing sleep disorders (SCI score ≥16) and must not have severe cognitive or major psychiatric disorders that could interfere with participation. Patients in emergency situations or under legal protection measures unable to consent are excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of or non-metastatic cancer,
  • Cancer treated with intravenous chemotherapy and/or immunotherapy administered intravenously or subcutaneously,
  • Age ≥ 18 years,
  • Ability to read and understand French,
  • Patient covered by a social security system,
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • SCI questionnaire score \<16
  • Diagnosed or controlled sleep disorders
  • Presence of severe cognitive disorders (e.g., Alzheimer's disease) or major psychiatric disorders (e.g., psychosis), as noted in the medical record, observed at recruitment, or reported by the patient
  • Patient in an emergency situation, or subject to a legal protection measure (guardianship, curatorship, or judicial protection) and unable to provide consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
260 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients who have just been diagnosed with cancer.

    These patients will be followed up with for one year.

06

What researchers measure

Primary outcomes

  1. The primary objective is to characterize the evolution, severity, and incidence of insomnia in patients newly diagnosed with cancer

    The primary objective of this longitudinal study is to diagnose insomnia and track its evolution and severity in patients newly diagnosed with cancer over the first year after diagnosis. Two validated questionnaires will be repeatedly administered: the Sleep Condition Indicator (SCI) and the Insomnia Severity Index (ISI). The SCI, based on DSM-5 criteria, identifies probable clinical insomnia by assessing symptom frequency, duration (difficulty falling asleep, night awakenings, early awakening), and functional impact. The ISI is a 7-item questionnaire evaluating perceived sleep difficulties over the past two weeks, including sleep initiation, maintenance, early awakening, daytime functioning, and distress. Total scores classify insomnia as absent, subclinical, moderate, or severe.

    Time frame: over a 12-month period

Secondary outcomes

  1. The secondary objective is to characterize Pain perception and the impact of pain on the patient's daily behaviour

    Pain perception and the impact of pain on the patient's daily behaviour will be assessed using the Concise Pain Questionnaire (QCD), the French version of the Brief Pain Inventory (BPI). This validated questionnaire assesses the impact of pain on seven general aspects of the patient's life (activity, mood, walking ability, work, relationships, sleep and enjoyment of life) (32, 33),

    Time frame: over a 12-month period

  2. The secondary objective is to characterize the patient's levels of anxiety and depression

    The patient's levels of anxiety and depression will be assessed using the validated Hospital Anxiety and Depression Scale (HADS). For each component (anxiety, depression), the score obtained is analysed: a score of 7 or below indicates an absence of symptoms, a score between 8 and 10 indicates uncertain symptoms, and a score of 11 or above indicates definite symptoms (34), * All treatments used to combat insomnia will be recorded, * The percentage of completed questionnaires will be calculated.

    Time frame: over a 12-month period

  3. The secondary objective is to characterize cancer-related anxiety/depression in patients newly diagnosed with cancer.

    Patient anxiety and depression will be assessed using the validated Hospital Anxiety and Depression Scale (HADS). Each subscale (anxiety and depression) is scored separately: ≤7 indicates no symptoms, 8-10 suggests borderline symptoms, and ≥11 reflects definite symptoms.

    Time frame: over 12-months period

07

Study locations

1 of 1 sites recruiting
  • 12 boulevard du Dr Chantemesse
    Le Puy-en-Velay, 43000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2028, 34 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 34 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Nov 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
2 added, 3 removed
What changed in the outcomes
  • AddedThe secondary objective is to characterize Pain perception and the impact of pain on the patient's daily behaviourTime frame: over a 12-month period
  • AddedThe secondary objective is to characterize the patient's levels of anxiety and depressionTime frame: over a 12-month period
  • RemovedThe secondary objective is to characterize the sleep quality in patients newly diagnosed with cancer.Time frame: over a 12-month period
  • RemovedThe secondary objective is to characterize cancer-related pain in patients newly diagnosed with cancer.Time frame: over a 12-month period
  • RemovedThe secondary objective is to characterize cancer-related quality of life in patients newly diagnosed with cancer.Time frame: over 12-months period
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Secondary outcomes 2 added, 3 removed
    What changed in the outcomes
    • AddedThe secondary objective is to characterize Pain perception and the impact of pain on the patient's daily behaviourTime frame: over a 12-month period
    • AddedThe secondary objective is to characterize the patient's levels of anxiety and depressionTime frame: over a 12-month period
    • RemovedThe secondary objective is to characterize the sleep quality in patients newly diagnosed with cancer.Time frame: over a 12-month period
    • RemovedThe secondary objective is to characterize cancer-related pain in patients newly diagnosed with cancer.Time frame: over a 12-month period
    • RemovedThe secondary objective is to characterize cancer-related quality of life in patients newly diagnosed with cancer.Time frame: over 12-months period
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07280416
Lead sponsor
Centre Hospitalier Emile Roux
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Dec 16, 2025
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Emilie GADEA, PhD
Contact
science.writer@ch-lepuy.fr
+33 471 043 538

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion